Doxorubicin-Trabectedin Strategy Boosts Survival in Challenging Sarcoma

Published Date: 09 Sep 2024

Combination for leiomyosarcoma improved OS by 9 months versus doxorubicin alone

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Added Plinabulin Boosts OS as Later-Line Treatment for EGFR Wild-Type NSCLC

2.

Blinatumomab Plus Chemotherapy New Standard for Children With B-Cell ALL

3.

Massachusetts nurses with brain tumors: Department of Public Health 'in communication' with Newton-Wellesley

4.

Recent research suggests that vitamin supplements may increase the risk of developing cancer.

5.

New First-Line Option for Advanced ALK-Positive Lung Cancer


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot